Begin typing your search above and press return to search.

One More antiviral drug gets DCGI nod to treat pandemic patients

By:  Tupaki Desk   |   21 Jun 2020 2:32 PM GMT
One More antiviral drug gets DCGI nod to treat pandemic patients
X
In the wake of India finding it very hard to combat the spread of the contagious disease, Indian generic pharmaceutical company Hetero stated that the Drug Controller General of India (DCGI) gave its nod to manufacture and market the antiviral drug COVIFOR.

COVIFOR, which is the generic version of Remdesivir will be made available in India soon. This drug will be used to treat patients who have mild to moderate symptoms of the pandemic.

Talking about DCGI giving its nod for the drug, Hetero Group Chairman Dr. B Partha Saradhi Reddy said that, the COVIFOR drug might be the game-changer in coming up with a potential vaccine to cure the virus. He said that, the drug banks high on its clinical outcomes.

The COVIFIR drug will be made available in 100 mg vials, which means the drug is injectable. Though the DCGI permitted the drug, the drug should be closely monitored by doctors and trained healthcare workers while treating a patient.

The other day, Glenmark Pharmaceuticals, another Indian Pharmaceutical company announced Favipiravir, an antiviral drug that will be sold under FabiFlu.